Body composition and physical function are related but separate outcomes. A trial reporting both should preserve the distinction and explain why follow-up ended. Primary study
What was reported
The trial randomized 395 adults aged 65–84 to capromorelin schedules or placebo. Planned two-year treatment ended early under predetermined treatment-effect criteria. Lean mass and selected performance measures favored treatment at reported time points. Adverse findings included fatigue, insomnia, and small increases in glucose-related measurements and insulin resistance. Primary report
Our appraisal: distinguish the planned study from the observed study
A two-year plan is not two years of completed evidence. Follow-up duration, completion counts, and the stopping rule determine how much information is available about persistence and safety.
Pooling active groups can answer a broad treatment question, but it may obscure differences among schedules. A pooled result should not be converted into proof that every tested schedule has the same balance of benefit and harm.
Lean mass should also remain separate from strength and independence. A change in measured tissue composition does not guarantee fewer falls, less disability, or improved daily life. Selected performance tests provide additional information, but their clinical importance and multiplicity need appraisal.
The glucose-related findings belong beside the potential benefits. Describing them as small does not make them irrelevant, especially when considering longer exposure or populations with different metabolic risk.
This study provides a mixed set of endocrine, body-composition, performance, and tolerability findings for a specific nonpeptide secretagogue. It does not establish an anti-aging treatment or permit the same claims to be assigned to peptide products that stimulate the GH axis through different pharmacology.
Frequently asked questions
How many participants were randomized?
Was the planned two-year treatment completed?
No.
Did lean mass favor treatment?
Yes, in the reported comparison.
Were all clinical benefits established?
No.
Were glucose-related changes reported?
Yes.
Is capromorelin a peptide product?
It is a nonpeptide secretagogue.
Does this validate every GH-stimulating compound?
No.